News | September 02, 2014

John Muir Health's Concord Medical Center First in Northern California to Use the FIRMap to Treat AFib

topera, catheter, FIRMmap

September 2, 2014 – John Muir Health's Concord medical center is the first hospital in Northern California and one of just 20 hospitals in the nation to begin treating patients who suffer from atrial fibrillation (AFib), the most common type of heart arrhythmia, with a new procedure that features the FDA cleared FIRMap Catheter.

A heart arrhythmia refers to the disorganization of the electrical impulses in the heart causing an irregular or rapid beat. AFib is an abnormal heart condition affecting more than 2.5 million Americans (more than the population of San Francisco, San Jose and Oakland combined) and is considered one of the most common arrhythmia problems in adults over the age of 65. Left untreated, atrial fibrillation can lead to serious consequences such as heart failure or stroke.

"To successfully treat AFib, the actual source must be identified, as well as the triggering cells. The exact areas in the upper chamber of the heart responsible for maintaining fibrillation have historically proven to be elusive resulting in a lower success rate than desired and creating frustration for patients and physicians," said Susan Eisenberg, M.D., cardiac rhythm center medical director at John Muir Health. "Using the FIRMap Catheter and 3-D mapping technology, the treatment results are far beyond any medication or surgical procedure previously available. We can now pinpoint the patient-specific source of arrhythmia with accuracy, which is critical as it allows us to address the cause of AFib in a single procedure with a very high rate of success."

Clinical trials showed that 82.4 percent of patients treated using the FIRMap Catheter and 3-D mapping technology were free of AFib after a single procedure versus 44.9 percent of those treated with the standard pulmonary vein isolation (PVI) approach. After three years, 77.8 percent of patients treated with the FIRM technology were free of AFib compared to 38.5 percent treated with the PVI approach.

"Previously, the treatment options were limited to a one-size fits all approach, which had a much lower success rate and, therefore, would need to be repeated," said Eisenberg. "Undergoing the procedure again is inconvenient for patients, means they still are living with AFib, increases their number of doctor visits and raises health care costs."

John Muir Health has performed the new procedure on 30 patients thus far with excellent results. Suzan Pemberton of Lafayette, Calif., recently had her AFib treated using the FIRMap catheter and 3-D mapping system.

"I only recently found out that I had AFib," said Pemberton. "This new treatment technology gives me peace of mind that the source has been found, it has been corrected and I can continue to travel and live my normal life."

The FIRMap catheter, developed by Topera Inc., is an innovative medical device that allows doctors to view specific areas in the heart, which could sustain an arrhythmia. This device, along with a ground-breaking 3-D mapping system, has become essential when performing the progressive procedure known as FIRM Guided ablation, which strives to detect and neutralize the source of electrical impulses or "rotors" disrupting the heart’s normal rhythm. Using this technology, the ablation procedure can target a patient-specific area of the heart, which is critical to that patient’s arrhythmia. The precision of the procedure ultimately aims to diminish recurrence rates among patients, thus generating a major feat in arrhythmia technology today.

For more information: www.johnmuirhealth.com

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init